Under construction – not a live service
Sign in
Taking people in AustriaNo phase

Registry study following adults with acute myeloid leukemia and related blood cancers

Collects health records and samples from adults with newly diagnosed or relapsed acute myeloid leukemia.

Key facts

Who runs it
University of Ulm
Where
Graz, Innsbruck, Linz, Rankweil, Salzburg, and Vienna, AustriaSee the 8 sitesAlso in 1 other country, 86 sites
Trial code
Registry title
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
Status
Recruiting
People taking part
50,000 people, planned
Started
6 Jul 2010
Expected to end
31 Dec 2044
Type of study
Observational
Record updated
5 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a suspected or confirmed diagnosis of acute myeloid leukemia or related blood cancers, newly diagnosed or relapsed/refractory. It records patient data and stores samples.

Age
18 years or older. There is no upper age limit.
Sex
All sexes can join.
Disease stage
Acute myeloid leukemia and related neoplasms, newly diagnosed or relapsed/refractory, classified according to the International Consensus Classification.

Main reasons for not taking part

  • Severe neurological or psychiatric disorder that interferes with giving informed consent
  • No consent for registration, storage and processing of patient and disease data and for informing the family physician
  • No consent for biobanking of biological samples and analyses on stored material

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients with suspected diagnosis of acute myeloid leukemia and related neoplasms, newly diagnosed or relapsed/refractory, classified according to the International Consensus Classification
  • Age ≥ 18 years. There is no upper age limit
  • Signed written informed consent

Who cannot take part

  • Severe neurological or psychiatric disorder interfering with ability to give an informed consent
  • No consent for registration, storage and processing of the individual patient and disease characteristics and course as well as information of the family physician about study participation
  • No consent for biobanking of patient's biological specimens and performance of analyses on stored material

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • How old are you?

Where in Austria

Also in 1 other country, 86 sites

  • Medizinische Universität GrazGraz, AustriaContact: Armin Zebisch, Prof. Dr.Taking people
  • Medizinische Universität InnsbruckInnsbruck, AustriaContact: David Nachbaur, Prof. Dr.Taking people
  • Kepler Universitatsklinikum GmbHLinz, AustriaContact: Clemens Schmitt, Prof.Taking people
  • Krankenhaus der Elisabethinen Linz GmbHLinz, AustriaContact: Michael Girschikofsky, Dr.Taking people
  • Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H.Linz, AustriaContact: Hartmut Döhner, Prof. Dr.No longer taking part
  • Landeskrankenhaus FeldkirchRankweil, AustriaContact: Bernd Hartmann, Dr.Taking people
  • Universitätsklinikum der PMU Landeskrankenhaus SalzburgSalzburg, AustriaContact: Lisa PleyerTaking people
  • Hanuschkrankenhaus WienVienna, AustriaContact: Elisabeth Koller, Dr.Taking people

About the trial

What the trial wants to find out

This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms

Read full original descriptionShow less

Investigator's sites: 80-90 sites in Germany and Austria

Estimated duration of observation of an individual patient:

10 years maximum

Objectives

* To register all patients with AML and related neoplasms, newly diagnosed or relapsed/refractory in all AMLSG participating centers (completeness) * To perform rapid analyses of disease-related genetic markers (incidences, treatment recommendations) * To assess patient and family history, as well as patient characteristics * To evaluate treatment response (CR, CRh, CRi) and outcome data (event-free survival [EFS], relapse-free survival [RFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS]) * To evaluate the impact of measurable residual disease (MRD) by different methods * To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers) * To store biosamples from all patients (e.g., bone marrow, blood, plasma, normal tissue; e.g., skin biopsy, finger nails, hairs, sputum, or urine)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
Plain-language title
Registry study following adults with acute myeloid leukemia and related blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT01252485, who can take part
Record updated
5 January 2026